Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13518087 | 0.84 | GSK3B (0.54) | KDM4EL3MBTL1GSK3BNPC1RAB9A | |
| SCHEMBL13518175 | 0.82 | GSK3B (0.44) | KDM4EL3MBTL1GSK3BSMN1; SMN2ALDH1A1 | |
| SCHEMBL6847689 | 0.82 | GSK3B (0.49) | KDM4EGSK3BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6847566 | 0.81 | GSK3B (0.51) | KDM4EL3MBTL1GSK3BNPC1RAB9A | |
| SCHEMBL6847605 | 0.79 | GSK3B (0.49) | KDM4EL3MBTL1GSK3BNPC1RAB9A | |
| SCHEMBL6847853 | 0.79 | GSK3B (0.51) | KDM4EL3MBTL1GSK3BSMN1; SMN2ALDH1A1 | |
| SCHEMBL6848101 | 0.79 | GSK3B (0.46) | KDM4EGSK3BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11366820 | 0.78 | KDM4E (0.59) | KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6847082 | 0.77 | KMT2A (0.55) | GSK3BNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6847892 | 0.77 | GSK3B (0.47) | KDM4EGSK3BRAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937091-B2 | Inhibitor of protein crosslinking and use of the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2015-01-20 | — | — | US | disclosed |
| US-8937091-B2 | Inhibitor of protein crosslinking and use of the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2015-01-20 | — | — | US | disclosed |
| US-8937091-B2 | Inhibitor of protein crosslinking and use of the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120277423-A1 | PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME | JAPAN SCIENCE AND TECHNOLOGY AGENCY | 2012-11-01 | — | — | US | disclosed |
| US-20120277423-A1 | PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME | JAPAN SCIENCE AND TECHNOLOGY AGENCY | 2012-11-01 | — | — | US | disclosed |
| WO-2011055561-A1 | PROTEIN CROSSLINKING INHIBITOR AND USE THEREOF | 独立行政法人科学技術振興機構 (JP) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277423-A1 | PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME | ARGLU1, F12, CDKL1 | KDM4E 1192/4885L3MBTL1 1521/4885GSK3B 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.